+

PL1676848T3 - Formy polimorficzne ryfaksyminy jako antybiotyki - Google Patents

Formy polimorficzne ryfaksyminy jako antybiotyki

Info

Publication number
PL1676848T3
PL1676848T3 PL06004220T PL06004220T PL1676848T3 PL 1676848 T3 PL1676848 T3 PL 1676848T3 PL 06004220 T PL06004220 T PL 06004220T PL 06004220 T PL06004220 T PL 06004220T PL 1676848 T3 PL1676848 T3 PL 1676848T3
Authority
PL
Poland
Prior art keywords
rifaximin
antibiotics
polymorphous forms
polymorphous
forms
Prior art date
Application number
PL06004220T
Other languages
English (en)
Inventor
Giuseppe C Viscomi
Manuela Campana
Dario Braga
Donatella Confortini
Vincenzo Cannata
Denis Severini
Paolo Righi
Goffredo Rosini
Original Assignee
Alfasigma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33187382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1676848(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alfasigma Spa filed Critical Alfasigma Spa
Publication of PL1676848T3 publication Critical patent/PL1676848T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1236Cooking devices induction cooking plates or the like and devices to be used in combination with them adapted to induce current in a coil to supply power to a device and electrical heating devices powered in this way
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • HELECTRICITY
    • H05ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05BELECTRIC HEATING; ELECTRIC LIGHT SOURCES NOT OTHERWISE PROVIDED FOR; CIRCUIT ARRANGEMENTS FOR ELECTRIC LIGHT SOURCES, IN GENERAL
    • H05B6/00Heating by electric, magnetic or electromagnetic fields
    • H05B6/02Induction heating
    • H05B6/10Induction heating apparatus, other than furnaces, for specific applications
    • H05B6/12Cooking devices
    • H05B6/1209Cooking devices induction cooking plates or the like and devices to be used in combination with them
    • H05B6/1245Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements
    • H05B6/1263Cooking devices induction cooking plates or the like and devices to be used in combination with them with special coil arrangements using coil cooling arrangements

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Electromagnetism (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
PL06004220T 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki PL1676848T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT002144A ITMI20032144A1 (it) 2003-11-07 2003-11-07 Forme polimorfe di rifaximina, processi per ottenerle e
EP04005541A EP1557421B1 (en) 2003-11-07 2004-03-09 Polymorphous form of rifaximin as antibiotic
EP06004220A EP1676848B1 (en) 2003-11-07 2004-03-09 Polymorphous forms of rifaximin as antibiotics

Publications (1)

Publication Number Publication Date
PL1676848T3 true PL1676848T3 (pl) 2009-07-31

Family

ID=33187382

Family Applications (3)

Application Number Title Priority Date Filing Date
PL04005541T PL1557421T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki
PL06004220T PL1676848T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki
PL06004219T PL1676847T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL04005541T PL1557421T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL06004219T PL1676847T3 (pl) 2003-11-07 2004-03-09 Formy polimorficzne ryfaksyminy jako antybiotyki

Country Status (38)

Country Link
US (5) US7045620B2 (pl)
EP (6) EP1676847B1 (pl)
JP (5) JP2005139161A (pl)
KR (4) KR20050043589A (pl)
CN (4) CN1613858A (pl)
AR (3) AR043547A1 (pl)
AT (3) ATE421965T1 (pl)
AU (2) AU2004200964A1 (pl)
BR (2) BRPI0402382A (pl)
CA (2) CA2460384A1 (pl)
CL (1) CL2004000498A1 (pl)
CO (1) CO5560083A1 (pl)
CY (3) CY1108017T1 (pl)
DE (4) DE602004019298D1 (pl)
DK (3) DK1676847T3 (pl)
ES (3) ES2244364T3 (pl)
HK (3) HK1073657A1 (pl)
HR (2) HRP20040265A2 (pl)
IL (2) IL160798A0 (pl)
IT (1) ITMI20032144A1 (pl)
JO (1) JO2470B1 (pl)
MA (1) MA27069A1 (pl)
MD (1) MD3653G8 (pl)
ME (1) ME00424B (pl)
MX (2) MXPA04002353A (pl)
NO (1) NO334950B1 (pl)
NZ (1) NZ531622A (pl)
PL (3) PL1557421T3 (pl)
PT (3) PT1676848E (pl)
RS (4) RS54568B1 (pl)
RU (1) RU2270200C2 (pl)
SI (3) SI1676848T1 (pl)
TN (2) TNSN04044A1 (pl)
TW (1) TWI285107B (pl)
UA (1) UA86384C2 (pl)
WO (1) WO2005044823A2 (pl)
YU (1) YU24804A (pl)
ZA (1) ZA200401948B (pl)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20080262024A1 (en) * 2003-11-07 2008-10-23 Giuseppe Claudio Viscomi Rifaximin compositions and method of use
US7906542B2 (en) * 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) * 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
PT1698630E (pt) * 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
KR20150132214A (ko) 2006-08-02 2015-11-25 샐릭스 파마슈티컬스 인코포레이티드 방사선 직장s상결장염의 치료를 위한 조성물 및 방법
ITMI20061692A1 (it) * 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
US20080159987A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Restless Legs Syndrome
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ITMI20071241A1 (it) * 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
EP2420226B1 (en) * 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
AU2016203925B2 (en) * 2007-07-06 2016-10-20 Lupin Limited Pharmaceutical compositions of rifaximin
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
KR101674382B1 (ko) 2008-02-25 2016-11-09 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
RU2519649C2 (ru) * 2008-02-26 2014-06-20 Саликс Фармасьютикалз, Лтд. Способы лечения заболеваний кишечника
US11779571B2 (en) * 2008-02-26 2023-10-10 Salix Pharmaceuticals, Inc. Methods for treating irritable bowel syndrome (IBS)
PT2294012E (pt) 2008-05-07 2014-10-15 Salix Pharmaceuticals Ltd Administração de um agente de limpeza intestinal e de um antibiótico para o tratamento de doença intestinal
US8980872B2 (en) 2008-09-26 2015-03-17 Aska Pharmaceutical Co., Ltd. Agent for preventing and/or treating functional gastrointestinal disorder
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
DK2350096T3 (da) 2008-10-02 2020-03-02 Salix Pharmaceuticals Ltd Fremgangsmåder til behandling af hepatisk encephalopati
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US20100317681A1 (en) * 2009-06-15 2010-12-16 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
KR20110107806A (ko) 2008-12-10 2011-10-04 시플라 리미티드 리팍시민 복합체
IT1397617B1 (it) * 2009-04-20 2013-01-18 Alfa Wassermann Spa Nuovi derivati della rifamicina
EP2437603A4 (en) * 2009-06-02 2012-12-12 Salix Pharmaceuticals Ltd METHODS OF TREATING HEPATIC ENCEPHALOPATHY
RU2582940C2 (ru) * 2009-09-13 2016-04-27 Саликс Фармасьютикалз, Лтд. Способы лечения синдрома раздраженного кишечника (срк)
KR20190000931A (ko) * 2009-10-27 2019-01-03 루핀 리미티드 리팍시민의 고형 분산물
WO2011061748A1 (en) * 2009-11-19 2011-05-26 Strides Arcolab Limited Rifaximin premix
WO2011061519A2 (en) 2009-11-23 2011-05-26 Cipla Limited Topical foam composition
EP2401282B2 (en) 2009-12-28 2017-01-04 Silvio Massimo Lavagna Method for the production of amorphous rifaximin
EP2536282A4 (en) 2010-02-18 2013-07-03 Salix Pharmaceuticals Ltd METHOD FOR THE TREATMENT OF INFECTIONS
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
BR112012030783A2 (pt) * 2010-06-03 2015-09-29 Salix Pharmaceuticals Ltd formas de rifaximina e seus usos
US8883795B2 (en) * 2010-06-16 2014-11-11 Apotex Pharmachem Inc. Polymorphic forms of Rifaximin
PH12013500082B1 (en) * 2010-07-12 2019-06-28 Salix Pharmaceuticals Ltd Formulations of rifaximin and uses thereof
WO2012035544A2 (en) 2010-09-13 2012-03-22 Sequent Scientific Ltd. A novel polymorphic form of rifaximin and process for its preparation
IT1403847B1 (it) * 2010-09-22 2013-11-08 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina e loro uso.
WO2012060675A1 (es) * 2010-11-05 2012-05-10 Interquim, S.A. De C.V. Proceso para la preparación de rifaximina amorfa
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
PL2672970T3 (pl) * 2011-02-11 2018-11-30 Salix Pharmaceuticals, Ltd. Postacie rifaksyminy i sposoby ich wykorzystania
AU2012251385A1 (en) 2011-05-02 2013-11-21 Ranbaxy Laboratories Limited Rifaximin dimethylformamide solvate
ITMI20110890A1 (it) * 2011-05-19 2012-11-20 A M S A Anonima Materie Sint & Affini S P A Polimorfo di rifaximina e processo per la sua preparazione
WO2012155981A1 (en) 2011-05-19 2012-11-22 Friulchem Spa New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
JP2014532723A (ja) * 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ,リミテッド 過敏性腸症候群(ibs)及び感染症を治療するための方法
JP2013184902A (ja) * 2012-03-06 2013-09-19 Aska Pharmaceutical Co Ltd リファキシミン含有結晶
CA2876737A1 (en) * 2012-06-13 2013-12-19 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014091432A1 (en) 2012-12-12 2014-06-19 Ranbaxy Laboratories Limited Pharmaceutical compositions of rifaximin
EP2971062A2 (en) 2013-03-15 2016-01-20 ALFA WASSERMANN S.p.A. Method for diagnosing vaginal infections
EA201591267A1 (ru) 2013-03-15 2016-03-31 Альфа Вассерманн С.П.А. Рифаксимин для применения в лечении вагинальных инфекций
KR102190173B1 (ko) 2013-04-12 2020-12-14 알파시그마 에스.피.에이. Nsaid 투여 및 관련 조성물, 방법 및 시스템
US9018225B1 (en) 2013-07-26 2015-04-28 Novel Laboratories Rifaximin crystalline forms and methods of preparation thereof
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2946101A1 (en) 2014-04-19 2015-10-22 Granules India Limited An improved process for the preparation of rifamycin derivatives
CN106795192B (zh) 2014-05-04 2020-06-16 萨利克斯药品公司 Ibs微生物群及其用途
EP3143027B1 (en) 2014-05-12 2019-07-10 Alfasigma S.p.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP3160467B1 (en) * 2014-06-30 2021-03-10 Salix Pharmaceuticals, Inc. Combination comprising rifaximin and cyclosporine for use in the treatment of bowel diseases
CN104083324B (zh) * 2014-07-10 2017-05-10 青岛动保国家工程技术研究中心有限公司 一种利福昔明的兽用悬乳剂及其制备方法和应用
EP2982764A1 (en) 2014-08-05 2016-02-10 ALFA WASSERMANN S.p.A. Identification of vaginal bacteria
CN104274391B (zh) * 2014-10-08 2017-02-01 哈尔滨坤盟医药科技有限公司 一种含利福昔明的药物制剂
WO2017021975A1 (en) * 2015-08-06 2017-02-09 Msn Laboratories Private Limited Process for the preparation of crystalline forms of rifaximin
EP3294270B1 (en) 2016-03-24 2018-09-12 Sandoz AG Pharmaceutical composition containing rifaximin alpha&delta
CA3003108C (en) 2016-03-24 2018-08-14 Sandoz Ag Storage stable composition comprising rifaximin alpha
US9988398B2 (en) * 2016-06-07 2018-06-05 Cadila Healthcare Limited Crystalline form of rifaximin and process for its preparation
EP4137132A1 (en) 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
CN106632396B (zh) * 2017-01-06 2019-01-11 成都樵枫科技发展有限公司 γ晶型利福昔明的制备方法和用途
ES2774553T3 (es) 2017-04-26 2020-07-21 Sandoz Ag Forma de dosificación oral que incluye rifaximina en forma beta
DK3645539T3 (da) 2017-06-26 2021-05-10 Biofer Spa Pyrido-imidazo-rifamycin-derivater som antibakterielt middel
US20220062183A1 (en) * 2018-12-19 2022-03-03 Friulchem S.P.A. Process for the manufacture of a tablet of rifaximin and tablet of rifaximin
CA3142214A1 (en) 2019-06-03 2020-12-10 Bausch Health Ireland Limited Use of methylnaltrexone and rifaximin for treatment of increased gut permeability or associated disorders
BR112022003500A2 (pt) 2019-09-24 2022-05-24 Bausch Health Ireland Ltd Formulações líquidas de rifaximina
WO2021191312A1 (en) 2020-03-24 2021-09-30 Bausch Health Ireland Limited Methods of treating covid-19 with rifaximin
WO2021229480A1 (en) * 2020-05-15 2021-11-18 Atra Pharmaceuticals Limited Polymorph of rifaximin, process for the preparation thereof and pharmaceutical composition containing rifaximin
KR20230028497A (ko) 2020-06-26 2023-02-28 보슈 헬스 아일랜드 리미티드 표적화된 방출 리팍시민 조성물
US20230398102A1 (en) 2020-10-29 2023-12-14 Bausch Health Ireland Limited Rifaximin liquid formulations for use inthe treatment of sickle cell disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241785A (en) * 1978-07-24 1980-12-30 Peerless Of America, Inc. Heat exchangers and method of making same
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
CA1215976A (en) 1984-05-15 1986-12-30 Vincenzo Cannata New process for the synthesis of imidazo rifamycins
IT1199413B (it) 1984-09-26 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
GB8816620D0 (en) * 1988-07-13 1988-08-17 Lepetit Spa Rifapentine hydrohalides
DE69111607T2 (de) * 1990-06-29 1995-12-21 Lepetit Spa Reine kristalline form von rifapentin.
KR20020071931A (ko) * 2000-01-07 2002-09-13 트렌스폼 파마수티컬스 인코퍼레이티드 다양한 고체-형태들의 고도의 자료 처리 편성, 확인 및분석
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002212340B2 (en) * 2000-10-31 2006-12-14 Sandoz Ag Crystalline forms of venlafaxine hydrochloride
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US20050262269A1 (en) 2004-05-20 2005-11-24 Pike Jimmy D System and method for information handling system PCI express advanced switching
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8633234B2 (en) * 2006-09-22 2014-01-21 Cipla Limited Rifaximin
WO2008115572A1 (en) 2007-03-21 2008-09-25 Theraquest Biosciences, Inc. Methods and compositions of nsaids
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
JP5755878B2 (ja) * 2007-07-06 2015-07-29 ルパン リミテッドLupin Limited リファキシミンの薬剤組成物
EP2420226B1 (en) 2007-07-06 2020-03-04 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) * 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
WO2009047801A1 (en) 2007-10-10 2009-04-16 Lupin Limited Therapeutic combinations and compositions for the treatment of gastrointestinal disorders
KR101674382B1 (ko) 2008-02-25 2016-11-09 샐릭스 파마슈티컬스 리미티드 리팍시민의 형태 및 이의 용도

Also Published As

Publication number Publication date
NO20061110L (no) 2006-04-19
EP1557421A1 (en) 2005-07-27
TNSN04044A1 (en) 2006-06-01
BRPI0402382A (pt) 2005-06-28
US20050272754A1 (en) 2005-12-08
US7045620B2 (en) 2006-05-16
PT1676847E (pt) 2009-04-09
DE602004019298D1 (de) 2009-03-19
RS20150291A1 (en) 2015-10-30
RU2270200C2 (ru) 2006-02-20
IL174271A (en) 2010-12-30
RS20060168A (en) 2008-09-29
US8173801B2 (en) 2012-05-08
ME00424B (me) 2011-10-10
JP2011057698A (ja) 2011-03-24
MD3653G8 (ro) 2016-08-31
US20080132530A1 (en) 2008-06-05
CA2538546A1 (en) 2005-05-19
AR081992A2 (es) 2012-10-31
US20110160449A1 (en) 2011-06-30
KR20060110737A (ko) 2006-10-25
CN1886408B (zh) 2010-06-09
CN101260114B (zh) 2012-11-28
HK1092150A1 (en) 2007-02-02
AU2004200964A1 (en) 2005-05-26
YU24804A (sh) 2006-08-17
AR081991A2 (es) 2012-10-31
MD3653F2 (en) 2008-07-31
MXPA06002644A (es) 2006-06-06
EP1676847A1 (en) 2006-07-05
WO2005044823A3 (en) 2005-10-27
CN1886408A (zh) 2006-12-27
AU2004287601B8 (en) 2009-03-05
DE602004006367T2 (de) 2007-09-06
JP2007509904A (ja) 2007-04-19
AU2004287601B2 (en) 2009-02-26
AU2004287601A1 (en) 2005-05-19
JP5635376B2 (ja) 2014-12-03
MA27069A1 (fr) 2004-12-20
SI1676847T1 (sl) 2009-06-30
US20050101598A1 (en) 2005-05-12
ITMI20032144A1 (it) 2005-05-08
US8404704B2 (en) 2013-03-26
RS20150292A1 (en) 2015-10-30
KR100855084B1 (ko) 2008-08-29
MD20060080A (en) 2006-11-30
ES2320160T4 (es) 2011-03-09
MXPA04002353A (es) 2005-05-11
ATE421965T1 (de) 2009-02-15
DE04005541T1 (de) 2005-12-29
CY1108909T1 (el) 2014-07-02
DK1557421T3 (da) 2007-09-17
RS54569B1 (en) 2016-06-30
US7915275B2 (en) 2011-03-29
PL1676847T3 (pl) 2009-07-31
EP1676847B1 (en) 2009-01-28
IL174271A0 (en) 2006-08-01
PT1676848E (pt) 2009-04-09
DE602004006367C5 (de) 2019-04-04
EP1682556A2 (en) 2006-07-26
PL1557421T3 (pl) 2007-08-31
KR100867751B1 (ko) 2008-11-10
EP1676848A1 (en) 2006-07-05
ATE361927T1 (de) 2007-06-15
IL160798A0 (en) 2004-08-31
EP2210893A1 (en) 2010-07-28
KR20070113327A (ko) 2007-11-28
DK1676847T3 (da) 2009-05-11
DE602004006367D1 (de) 2007-06-21
JO2470B1 (en) 2009-01-20
WO2005044823A2 (en) 2005-05-19
KR20050043589A (ko) 2005-05-11
NZ531622A (en) 2004-10-29
HRP20060093B1 (hr) 2015-12-18
ES2244364T3 (es) 2007-12-01
RU2004108953A (ru) 2005-10-27
UA86384C2 (uk) 2009-04-27
BRPI0407149A8 (pt) 2019-01-15
ZA200401948B (en) 2004-04-29
RS54568B1 (en) 2016-06-30
EP1676848B1 (en) 2009-01-28
CA2460384A1 (en) 2005-05-07
CN1613858A (zh) 2005-05-11
JP5199576B2 (ja) 2013-05-15
ATE421966T1 (de) 2009-02-15
DK1676848T3 (da) 2009-05-11
ES2320161T3 (es) 2009-05-19
EP1557421B1 (en) 2007-05-09
CN101260115B (zh) 2011-11-23
TWI285107B (en) 2007-08-11
KR100883216B1 (ko) 2009-02-13
HK1092151A1 (en) 2007-02-02
CY1108017T1 (el) 2013-09-04
TNSN06069A1 (en) 2007-10-03
JP2005139161A (ja) 2005-06-02
BRPI0407149A (pt) 2006-02-07
JP2011046738A (ja) 2011-03-10
SI1557421T1 (sl) 2007-08-31
CO5560083A1 (es) 2005-09-30
TW200515913A (en) 2005-05-16
CL2004000498A1 (es) 2005-03-11
NO334950B1 (no) 2014-08-04
JP2014177500A (ja) 2014-09-25
CY1108964T1 (el) 2014-07-02
ES2244364T1 (es) 2005-12-16
HK1073657A1 (en) 2005-10-14
PT1557421E (pt) 2007-07-31
CA2538546C (en) 2011-04-19
CN101260114A (zh) 2008-09-10
RS54571B1 (en) 2016-06-30
CN101260115A (zh) 2008-09-10
HRP20060093A2 (en) 2006-05-31
AR043547A1 (es) 2005-08-03
DE602004019296D1 (de) 2009-03-19
US20120059023A1 (en) 2012-03-08
EP2208730A1 (en) 2010-07-21
ES2320160T3 (es) 2009-05-19
HRP20040265A2 (en) 2004-12-31
KR20070113326A (ko) 2007-11-28
SI1676848T1 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
IL174271A0 (en) Polymorphous forms of rifaximin as antibiotics
HK1093483A1 (en) Polymorphic form of n-
IL169905A0 (en) Novel 2-pyridinecarboxamide derivatives
GB0304424D0 (en) Novel compounds
EP1648885A4 (en) NEW CONNECTIONS
EP1620101A4 (en) POLYMORPHS OF CABERGOLIN
GB0312368D0 (en) Novel ureido- and amido-pyrazolone derivatives
GB0315629D0 (en) New uses for antibiotic
GB0304809D0 (en) Novel compounds
GB0302431D0 (en) Novel compounds
GB0302546D0 (en) Novel compounds
ZA200507475B (en) Derivatives of azithromycin
GB0302008D0 (en) Antibiotic derivatives
PL378080A1 (pl) Sposób wytwarzania K-252A
GB0303767D0 (en) Gentamycin antibiotics
GB0303874D0 (en) Novel antibacterial compounds
TW568246U (en) Gasifying kiln
PL114147U1 (en) Interior decoration element
GB0301592D0 (en) Novel compounds
GB0301589D0 (en) Novel compounds
GB0303464D0 (en) Novel compounds
GB0301591D0 (en) Novel compounds
GB0304811D0 (en) Novel compounds
GB0301872D0 (en) Novel compounds
GB0301608D0 (en) Novel compounds
点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载